Influence of Sepsis, Age and SLCO1A2 Genetic Polymorphisms on Rocuronium Pharmacokinetics-pharmacodynamics in ASA I-III Surgical Patients

Trial Profile

Influence of Sepsis, Age and SLCO1A2 Genetic Polymorphisms on Rocuronium Pharmacokinetics-pharmacodynamics in ASA I-III Surgical Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Rocuronium bromide (Primary) ; Fentanyl; Midazolam; Propofol
  • Indications Neuromuscular blockade
  • Focus Pharmacokinetics
  • Acronyms ROCSEPSIS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Apr 2017 New trial record
    • 14 Apr 2017 Results assessing the influence of genetic polymorphisms of SLCO1A2 on the pharmacokinetics of rocuronium published in the European Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top